UnitedHealth: This Rally Is Lacking Substance; Sell Now

Despite a 33.5% rally, the author maintains an 'Underperform/Sell' rating on UnitedHealth (UNH), asserting the surge lacks fundamental basis. Key concerns include medical cost trends projected to worsen to 10% in FY26, outpacing pricing growth and exacerbated by the OBBBA, broadening DoJ probes into OptumRx, and a 91% valuation premium (21.2x fwd P/E) driven by multiple expansion rather than earnings. While acknowledging positive Medicare Advantage Star ratings, the author dismisses recent superinvestor buys as delayed and insufficient to offset these significant headwinds and technical resistance.

Analysis

Despite a recent 33.5% rally, a detailed analysis of UnitedHealth (UNH) presents a strongly bearish case, arguing the surge lacks fundamental substance. The core issue remains significant margin pressure on the insurance business, driven by a medical cost trend expected to hit 7.5% in FY25 and worsen to 10% in FY26, outpacing pricing growth. This headwind is compounded by legislative pressure from the 'One Big Beautiful Bill Act' (OBBBA), which is projected to cut Medicaid spending and Medicare reimbursements by approximately $500 billion. Furthermore, regulatory risk has intensified as the Department of Justice (DoJ) investigation has broadened from Medicare Advantage billing to include the OptumRx pharmacy benefit manager, creating a potential multi-billion dollar liability. The recent rally is attributed to hype-driven multiple expansion rather than improved earnings expectations; UNH is trading at a 21.2x forward P/E, a 91% premium to its peers, substantially above its historical 41% premium. The bullish catalyst of superinvestor buys, reported in Q2 FY25 13F filings, is dismissed as being based on delayed data from June 2025, after which the stock fell 25% before rallying. While the high percentage (78%) of Medicare Advantage plans with 4+ Star ratings provides a modest positive through bonus payments, it is viewed as insufficient to counteract the array of fundamental, regulatory, and valuation-based concerns.

Key Decisions for Investors

• Investors should re-evaluate long positions, as the analysis suggests the recent rally is driven by multiple expansion rather than fundamental improvement, indicating a high risk of reversal.
• Monitor developments in the Department of Justice's probe into OptumRx and forward-looking commentary on medical cost trends, as these are the primary catalysts for the bearish thesis.
• Exercise caution when using 13F filings as a primary investment signal, as the data's significant lag may not reflect the current positioning of institutional investors, particularly after sharp price movements.
• Consider the stock's current 91% forward P/E premium to peers as a sign of potential relative overvaluation, suggesting better risk-reward opportunities may exist elsewhere in the sector.
• For those with a bearish conviction, the technical analysis suggests the stock's rally to a key resistance level against the S&P 500 may present a strategic opportunity to initiate or add to short positions.